COM:4DMOLECULARTHERAPEUTICS
4D Molecular Therapeutics Inc
- Stock
Last Close
7.99
22/11 21:00
Market Cap
1.20B
Beta: -
Volume Today
2.60K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|
average inventory | -4.25M - | -4.25M 0% | -2.89M 31.93% | |||||
average payables | 707K - | 1.35M 90.81% | 1.77M 30.87% | 3.28M 85.53% | 4.04M 23.43% | 3.42M 15.45% | ||
average receivables | 722.50K - | 1.05M 45.47% | 1.23M 17.22% | 766.50K 37.78% | 23.50K 96.93% | 350K 1,389.36% | ||
book value per share | -1.32 - | -2.20 66.89% | -4.92 123.19% | 39.87 910.59% | -7.46 118.72% | -9.72 30.23% | 0.01 100.08% | |
capex per share | -0.04 - | -0.03 14.37% | -0.22 552.83% | -0.16 27.97% | -0.33 111.26% | -0.36 8.54% | ||
capex to depreciation | -0.92 - | -0.59 35.11% | -3.19 437.10% | -0.69 78.28% | -3.02 335.29% | -2.97 1.44% | ||
capex to operating cash flow | -0.07 - | 0.03 136.62% | 0.09 242.51% | 0.02 77.49% | 0.13 570.84% | 0.13 0.99% | ||
capex to revenue | -0.10 - | -0.03 70.39% | -0.46 1,464.84% | -0.07 83.98% | -0.51 587.47% | -3.69 629.99% | ||
cash per share | 1.61 - | 7.33 355.96% | 3.35 54.34% | 43.03 1,185.77% | 14.79 65.62% | 11.74 20.63% | 0.01 99.94% | |
days of inventory on hand | ||||||||
days payables outstanding | ||||||||
days sales outstanding | 20.24 - | 29.03 43.48% | 51.10 75.99% | 39.85 22.02% | 0.95 97.61% | |||
debt to assets | 0.00 - | 0.00 48.62% | 0.05 - | 0.06 32.34% | 0.04 29.90% | |||
debt to equity | -0.00 - | -0.00 29.49% | -0.08 - | -0.05 35.48% | 0.05 192.96% | |||
dividend yield | ||||||||
earnings yield | -0.02 - | -0.02 0.85% | -0.09 367.70% | -0.21 140.75% | -0.11 47.08% | -0.14 25.31% | -0.00 99.91% | |
enterprise value | 576.98M - | 415.23M 28.03% | 551.18M 32.74% | -10.18M 101.85% | 309.42M 3,139.68% | 516.00M 66.76% | 792.54B 153,492.38% | |
enterprise value over ebitda | -54.20 - | -42.80 21.03% | -13.96 67.38% | 0.18 101.32% | -4.34 2,453.11% | -4.69 8.11% | -7.02K 149,634.44% | |
ev to operating cash flow | 70.05 - | -25.55 136.47% | -15.01 41.23% | 0.20 101.33% | -4.48 2,338.37% | -5.95 33.00% | -10.46K 175,567.03% | |
ev to sales | 99.65 - | 29.39 70.51% | 78.90 168.49% | -0.75 100.95% | 17.15 2,393.83% | 164.91 861.35% | ||
free cash flow per share | 0.52 - | -1.33 357.71% | -2.69 102.09% | -8.07 200.03% | -2.82 65.05% | -3.04 7.60% | -0.00 99.94% | |
free cash flow yield | 0.01 - | -0.03 357.71% | -0.07 102.09% | -0.19 193.15% | -0.13 33.96% | -0.14 6.29% | -0.00 99.93% | |
graham net net | -1.54 - | -2.55 65.94% | -5.45 113.43% | 38.24 801.92% | -5.57 114.57% | 10.80 293.82% | 0.01 99.94% | |
graham number | 4.74 - | 6.15 29.74% | 19.87 223.09% | 88.81 346.91% | 20.34 77.10% | 26.14 28.53% | 0.02 99.92% | |
income quality | -0.73 - | 1.70 331.85% | 0.74 56.24% | 0.90 20.61% | 0.97 7.95% | 0.81 16.81% | 0.75 6.79% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | 0 | |
interest coverage | 17.14 - | |||||||
interest debt per share | 0.00 - | 0.01 116.11% | 0.59 - | 0.30 49.42% | 0.00 99.88% | |||
inventory turnover | ||||||||
invested capital | -0.00 - | -0.00 29.49% | -0.08 - | -0.05 35.48% | 0.05 192.96% | |||
market cap | 600.83M - | 506.99M 15.62% | 600.83M 18.51% | 266.55M 55.64% | 608.41M 128.25% | 718.52M 18.10% | 792.78B 110,234.36% | |
net current asset value | -22.41M - | -30.49M 36.04% | -78.70M 158.12% | 250.71M 418.58% | -245.05M 197.74% | 190.00M 177.53% | 264.53M 39.22% | |
net debt to ebitda | 2.24 - | 9.46 322.18% | 1.26 86.70% | 5.01 298.52% | 4.19 16.36% | 1.84 56.09% | 2.08 12.85% | |
net income per share | -0.76 - | -0.76 0.85% | -3.57 367.70% | -8.79 146.40% | -2.46 71.99% | -3.12 26.86% | -0.00 99.92% | |
operating cash flow per share | 0.56 - | -1.30 333.83% | -2.47 90.60% | -7.92 219.92% | -2.49 68.51% | -2.68 7.48% | -0.00 99.93% | |
payables turnover | ||||||||
receivables turnover | 18.04 - | 12.57 30.30% | 7.14 43.18% | 9.16 28.24% | 383.79 4,089.74% | |||
research and ddevelopement to revenue | 2.34 - | 1.30 44.57% | 5.54 326.49% | 3.90 29.70% | 3.40 12.70% | 25.65 653.98% | ||
return on tangible assets | -0.41 - | -0.10 76.02% | -0.91 822.96% | -0.20 78.43% | -0.19 1.47% | -0.39 99.79% | -0.30 23.14% | |
revenue per share | 0.39 - | 1.13 189.21% | 0.47 58.28% | 2.12 349.51% | 0.65 69.27% | 0.10 85.13% | ||
roe | 0.57 - | 0.35 39.57% | 0.73 109.55% | -0.22 130.40% | 0.33 249.61% | 0.32 2.59% | -0.33 201.92% | |
roic | 0.57 - | 0.41 28.05% | 0.75 81.38% | -0.22 129.51% | 0.39 278.01% | 0.37 6.58% | -0.33 191.32% | |
sales general and administrative to revenue | 0.60 - | 0.44 27.57% | 1.99 355.72% | 1.27 36.33% | 1.55 22.62% | 10.52 577.26% | ||
shareholders equity per share | -1.32 - | -2.20 66.89% | -4.92 123.19% | 39.87 910.59% | -7.46 118.72% | -9.72 30.23% | 0.01 100.08% | |
stock based compensation to revenue | 0.04 - | 0.10 120.41% | 0.51 420.12% | 0.37 27.76% | 0.76 108.93% | 5.47 615.26% | ||
tangible asset value | -19.59M - | -27.59M 40.82% | -72.97M 164.51% | 256.39M 451.36% | -207.00M 180.74% | 231.34M 211.76% | 307.83M 33.07% | |
tangible book value per share | -1.32 - | -2.20 66.89% | -4.92 123.19% | 39.87 910.59% | -7.46 118.72% | 7.15 195.80% | 0.01 99.89% | |
working capital | 18.59M - | 86.01M 362.66% | 39.55M 54.02% | 265.91M 572.29% | 299.09M 12.48% | 204.78M 31.53% | 277.64M 35.58% |
All numbers in USD (except ratios and percentages)